Pulmonary arterial hypertension (PAH) is progressive disorder characterized by elevated pulmonary vascular resistance that can lead to right heart failure and death. One of the main therapeutic options for PAH are medications targeting the prostacyclin pathway. Treprostinil is a prostacyclin analogue and selexipag is a selective IP receptor agonist. Treprostinil can be delivered by a variety of routes including oral, inhaled, subcutaneous and intravenous. Selexipag is currently approved as an oral formulation. The impact of the route of delivery and the optimal dosing for transitioning inhaled treprostinil to oral treprostinil or selexipag is unknown. More importantly, given the different selectivity for prostacyclin receptors, it is uncertain whether treprostinil and selexipag can be substituted. We present two patients with PAH who received medications targeting the prostacyclin pathway and were transitioned from inhaled treprostinil to either oral treprostinil or selexipag. In both cases, we noted clinical, functional and hemodynamic deterioration. These cases highlight that the route of delivery (inhaled versus oral) and/or the specific PH medication (treprostinil versus selexipag) matter; therefore close monitoring during transitions is imperative.
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Pulmonary arterial hypertension (PAH) is progressive disorder that if left untreated leads to right heart failure and death. 1 Scarce data from small case series is available to guide the transition among different treprostinil products. 4,8e12 A case report exists on the transition of inhaled treprostinil to oral selexipag. 13 It remains unknown whether PH therapies that act in the prostacyclin pathway are similarly efficacious when delivered orally or by the inhaled route. We present two patients in whom transition from inhaled treprostinil to either oral treprostinil or selexipag had a major impact on clinical, functional and hemodynamic parameters, Abbreviations: 6WMD, Six-minute walk distance; PAH, pulmonary arterial hypertension; RVSP, right ventricular systolic pressure; FDA, Food and Drug Administration; BMI, body mass index; NYHA, New York Heart Association; WHO, World Health Organization; RHC, right heart catheterization.
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stressing that caution must be exercised when considering switching routes of delivery of treprostinil or transitioning treprostinil to selexipag.
Case 1 description
A 51-year-old man with heritable PAH received treatment with sildenafil 20 mg every 8 h. Given persistent symptoms inhaled treprostinil was added (9 inhalations (54 mg) four times a day). The patient noticed symptomatic improvement with an increase in sixminute walked distance (6MWD) and a pronounced decrease in pulmonary vascular resistance (PVR). The patient's condition remained stable during a 4-year period; however, he reported difficulties in adhering with inhaled treprostinil 4 times a day. Therefore, he was switched to oral treprostinil with the dose titrated up to maximum tolerated (3 mg three times daily). Both before and after this transition he was also treated with tadalafil 40 mg daily and bosentan 125 mg twice a day. A few months after receiving oral treprostinil he started having progressive dyspnea, nausea, leg pain, and fatigue. An echocardiogram revealed dilation of the right ventricle (RV) and a right heart catheterization (RHC), repeated after 15 months of receiving oral treprostinil, showed hemodynamic deterioration. Since the patient declined parenteral prostacyclin analogues, he was transitioned back to inhaled treprostinil (9 inhalations (54 mg) 4 times a day) with improvement of his hemodynamic profile (Table 1) .
Case 2 description
A 50-year-old woman with PAH due to connective tissue disease was treated with bosentan 62.5 mg twice a day immediately after diagnosis. Due to persistent symptoms (NYHA III), first tadalafil 40 mg daily and then inhaled treprostinil (9 inhalations (54 mg) four times daily) were added. Under this combination, the patient had symptomatic and echocardiographic improvement. During the 4-year follow-up, the patient's condition remained stable; however, she encountered difficulties in using inhaled treprostinil 4 times a day. Therefore, the patient was switched to oral selexipag with a dose titrated up to the maximum tolerated, i.e. 1400 mg twice daily.
On oral selexipag the patient experienced diarrhea and progressive dyspnea through the course of a few months. In addition, an echocardiogram obtained 2 months after initiation of oral selexipag showed an increase in right ventricular basal diameter and estimated right ventricular systolic pressure. Thus, the patient was switched back to inhaled treprostinil (9 inhalations (54 mg) 4 times a day) which resulted in clinical and echocardiographic improvement of her condition ( Table 2 ).
Discussion
Our study highlights the challenges in transitioning PH medications that work on the prostacyclin pathway from the inhaled to oral route of administration, even when maximum tolerated doses of the oral medication were provided. The cases presented emphasize the critical need to closely monitor these patients both during and after transition to be able to promptly manage a potential deterioration of their disease. Interestingly, when patients were switched back from oral (treprostinil or selexipag) to inhaled treprostinil their condition improved.
Inhaled and oral treprostinil offer the advantage of avoiding certain risks associated with the parental administration of prostacyclin analogues, such as infusion site pain, line dislodgment, and skin and bloodstream infections. 4 Inhaled treprostinil is generally well tolerated with side effects (occurring in 10% of patients) including cough, headache, nausea, dizziness, flushing, throat irritation, pharyngeal/laryngeal pain and diarrhea. 4 Bioavailability is around 64e72%, time to peak between 0.12 and 0.25 h and terminal half-life of 4 h (package insert). Side effects of oral treprostinil (occurring in 10% of patients) include headache, nausea, diarrhea, jaw pain, vomiting, flushing and pain on the extremities. 5 Oral absorption of treprostinil is increased when administered after a high-fat, high calorie meal with a bioavailability of w17% and a time to peak around 4e6 h. Both the inhaled and oral routes of administration require up-titration. The inhaled form of treprostinil is given 4 times a day while the oral formulation is administered every 8e12 h.
14 Limited information exists on transitioning inhaled to oral treprostinil or vice versa. Coleman et al 15 reported their experience in 8 pediatric patients (10e20 years old) with clinically stable PAH (5 idiopathic and 3 associated with congenital heart disease) in whom 5 subjects were transitioned from inhaled to oral treprostinil These transitions were successful, but one patient later discontinued oral treprostinil due to migraines. 15 Jorgensen et al 11 transitioned 6 pediatric patients (7e21 years old) with PAH from inhaled (average dose of 172 mg/day) to oral treprostinil (average dose of 3.5 mg/day) and of them, 3 experienced side effects (nausea, diarrhea, and loss of appetite) and one had sudden death (unclear if related to the transition or other factors). 11 Coons et al 10 transitioned 2 patients with PAH from inhaled (72 mg 4 times a day) to oral treprostinil (2.5 mg for one and 4 mg for the other subject, given every 8 h). Both patients had side effects including headache, jaw pain, diarrhea and flushing. In one subject the dose was increased to 7 mg every 6 h (week 52 from initial transition), while the other patient was later enrolled in hospice. 10 Khan et al 12 transitioned 2 PAH patients from inhaled (54 and 72 mg 4 times a day) to oral treprostinil (3 mg every 8 h). In both patients the 6MWD improved and NYHA functional class remained stable. 12 These data suggest that the transition from inhaled to oral treprostinil is feasible and that headaches and gastrointestinal side effects are expected. At the end of the transition the oral dose of treprostinil was usually around 2.5e4 mg every 8 h. Our patient, in case 1, was transitioned from inhaled (54 mg every 6 h) to oral treprostinil 3 mg every 8 h, a dose that falls in the range described. 10e12, 15 Treprostinil was initially given as 4 mg twice a day, but rapidly increased to 3 mg thrice a day. Chakinala et al transitioned patients from parenteral to oral treprostinil and noted that the oral dose of the medication appears to be better tolerated when given 3 instead of 2 times a day, possibly by reducing the peak:trough fluctuations.
16
Selexipag is an oral selective IP prostacyclin receptor agonist. Side effects noted in more than 10% of the patients include headache, diarrhea, nausea, jaw pain, vomiting, pain in extremities, myalgia, flushing.
6 Selexipag is titrated to the highest tolerated or the maximum dose of 1600 mg twice daily. 6 Oral selexipag is characterized by rapid absorption (maximum plasma concentration within 1e3 h), bioavailability of 50% and terminal half-life of 0.8e2.5 h which is extended by an active metabolite to 6.2e13.5 h 17 (package insert). A recent case report described a successful transition (defined by stable NYHA functional class and estimated RVSP) from inhaled treprostinil (12 inhalations (72 mg) 4 times daily) to oral selexipag (1600 mg twice daily) over a period of 8 weeks. 13 Future results from an ongoing study (NCT02471183, TRANSIT-1: study to assess the tolerability and the safety of the transition from inhaled treprostinil to oral selexipag in patients with PAH) will help guide this transition. It remains unclear whether the route of administration and the type of medications that work on the prostacyclin pathway may influence the treatment efficacy. In the cases presented, inhaled treprostinil was transitioned to either oral treprostinil or selexipag with associated worsening of PAH that then partially improved after switching back to inhaled treprostinil. These different responses may suggest either a reduced gastrointestinal absorption with lower systemic levels of the medication in certain patients, a preferential (local) effect of the inhaled medication directly on the pulmonary vasculature, and/or intrinsic differences between treprostinil and selexipag that have differential effects on prostacyclin receptors. 18 We believe that our patients were compliant in taking either the inhaled or oral PAH medications. We have no reason to believe that they preferentially did not take to oral formulation. Further research is needed to better understand the discordant response noted between inhaled and oral medications in these 2 patients.
Conclusions
Pulmonary arterial hypertension medications may have different effectiveness depending on the route of administration (inhaled versus oral) and/or the type of medication used (treprostinil versus selexipag). Further investigations are needed to better guide these transitions and identify patients in whom switching from inhaled to oral formulation might not be appropriate. 
